BeStock  
Home › Stocks › Momentum

BeStock Momentum

A rules-based strategy, not a recommendation: every week it ranks BeStock's full coverage by trailing 12-month price return and holds the top 10 names that are also trading above their own 200-day average, inverse-volatility weighted and scaled to a volatility target. A holding is dropped immediately if it loses its own 200-day average. Updated daily.

Total return+401.7%
Annualized (CAGR)+31.5%
S&P 500, same stretch+99.2%
Trading days on file1,483
Win rate50.4%
Profit/loss ratio2.42
Sharpe ratio1.08

Methodology & limitations

Every week, every stock BeStock covers is ranked by its trailing 12-month (252-session) price return using only prices known as of that date. The model portfolio holds the 10 strongest names that are also trading above their own 200-day average and that have a positive trailing P/E no higher than 100 — momentum leaders that have broken down, or that have no earnings behind the move, are skipped — inverse-63-day-volatility weighted (capped at 18% per name) and scaled to an 18% annualised-volatility target, with the remainder held as cash. A holding is dropped immediately, any day, if it closes below its own 200-day average, not just at the weekly reconstitution. The chart below lines the strategy up against real S&P 500 and Nasdaq‑100 returns (from weekly SPY/QQQ closes, forward-filled onto this daily calendar and rebased to $100 on the same start date, which is why those two lines move in weekly steps) and against BeStock’s own coverage-wide average — the equal-weight return of every covered stock that day, which was the only comparison possible before real index data was added.

What this is not: a real, tradable fund; a projection of future returns; or a BeStock recommendation to buy or sell anything. It is a backtest of a mechanical rule against historical prices, computed daily and shown as-is. Returns assume an estimated 0.1% cost per trade; they do not account for slippage or taxes. A concentrated 10-stock portfolio can also become heavily weighted toward one hot sector when several momentum leaders move together at once — that has happened in the period below, and it is a real risk, not just a historical curiosity. Past performance, backtested or real, does not guarantee future results. This page is generic, impersonal information published the same way to every visitor — it does not take your financial situation, goals, or risk tolerance into account, and BeStock is not your investment adviser or broker.

Computed 2026-11-22 10:00:48. More on how BeStock builds its pages.

Want to try your own version? Set your own stock count, market-cap / P/E / sector filters and date range →

Equity curve

92108127148173Nov 20, '25May 22, '26Nov 20, '26
  • BeStock Momentum +13.0%
  • S&P 500 (SPY) +5.8%
  • Nasdaq-100 (QQQ) +3.6%
  • Coverage-wide average +18.8%

Growth of $100 invested at the start of the shown window, marked to market every trading day — shown on a log scale so the strategy’s much larger multiple and the benchmarks’ smaller ones stay readable on the same chart.

Year by year

“vs S&P” is the strategy’s return that year minus the S&P 500’s (simple percentage-point gap, i.e. alpha). “Max drawdown” is the worst peak-to-trough decline in the strategy’s own equity curve within that calendar year. BeStock Momentum has no index-level market-timing switch; its cash sleeve comes only from volatility-targeted position sizing and per-name 200-day stops.

2020* covers 28 Dec 2020–31 Dec 2020 only (the backtest’s start date), not the full calendar year. 2026 (YTD) covers 1 Jan–20 Nov 2026 so far, not a completed year. Both are shown for completeness but aren’t directly comparable to the full-year rows.

YearBeStock MomentumS&P 500Nasdaq-100vs S&PMax drawdown
2020*+0.0%+0.0%+0.0%+0.0%0.0%
2021-0.6%+28.8%+27.4%-29.4%-22.2%
2022+25.4%-18.2%-32.6%+43.6%-19.4%
2023+34.3%+26.2%+54.8%+8.1%-17.5%
2024+99.2%+26.1%+27.4%+73.0%-14.6%
2025+45.8%+16.8%+18.8%+29.1%-20.0%
2026 (YTD)+3.2%+1.8%-0.4%+1.4%-32.5%

Current holdings

TickerCompanySectorPriceHeld sinceSince entryWeightTrailing 252-day momentum
CDNACareDx–$70.0029 Sep 2026 (52d)+9.3%4.6%+338%
ETONEton PharmaceuticalDrug Manufacturers - Specialty & Generic$60.8510 Nov 2026 (10d)-9.9%4.6%+261.8%
EVCEntravision Communications–$8.6410 Nov 2026 (10d)-5.2%5.2%+247.3%
VSXYVictoria's SecretApparel Retail$94.573 Nov 2026 (17d)-5.9%5.6%+171.8%
ECOOkeanis Eco TankersMarine Shipping$84.8320 Nov 2026 (0d)+0%5.7%+167.5%
IRDMIridium CommunicationsTelecom Services$42.0810 Nov 2026 (10d)-8.8%11.4%+165.1%
SEZLSezzle–$137.4217 Nov 2026 (3d)-10.9%5.0%+163.6%
CBRLCracker Barrel Old Country Store IncRestaurants$70.7520 Nov 2026 (0d)+0%6.0%+162.7%
PACSPACS GroupMedical Care Facilities$43.6720 Oct 2026 (31d)-8.5%7.8%+159.5%
RNGRingCentral–$66.6117 Nov 2026 (3d)-7.5%6.7%+153.6%

As of 20 Nov 2026. “Since entry” is this position’s actual return from the model’s buy price to today (the realized/unrealized P&L); “Weight” is this position’s current share of the model portfolio (inverse-63-day-volatility weighted, capped at 18%/name); “Trailing 252-day momentum” is the 12-month price-return ranking factor that got it picked, not its return in the portfolio - the two numbers measure different things. Sector is the stock’s primary industry classification — worth scanning for concentration, per the note above. Not a recommendation to buy or sell.

Previously held

TickerCompanySectorEntry dateEntry priceExit dateExit priceReturnHeld
HNGEHinge HealthHealth Information Services10 Nov 2026$123.2320 Nov 2026$105.78-14.2%10d
LBRXLB PharmaceuticalsBiotechnology10 Nov 2026$44.9420 Nov 2026$38.85-13.6%10d
ATEXAnterix–6 Oct 2026$83.4117 Nov 2026$78.86-5.5%42d
PAYSPaySignSoftware - Infrastructure3 Nov 2026$15.1310 Nov 2026$10.14-33%7d
FETForum Energy Technologies–3 Nov 2026$76.9310 Nov 2026$72.08-6.3%7d
FIGSFIGS Inc–3 Nov 2026$20.8210 Nov 2026$22.39+7.5%7d
ASXASE TechnologySemiconductors15 Sep 2026$37.123 Nov 2026$39.05+5.2%49d
DELLDell TechnologiesComputer Hardware8 Sep 2026$533.883 Nov 2026$408.40-23.5%56d
IMOSChipMOS TECHNOLOGIESSemiconductors20 Oct 2026$60.953 Nov 2026$52.17-14.4%14d
OMEROmerosBiotechnology24 Aug 2026$19.3220 Oct 2026$16.55-14.3%57d

Every stock the model has bought and later sold that is not in the current holdings table above. One row per completed buy/sell round trip — the same stock can appear more than once if it was bought and sold on separate occasions. Return is the realized gain/loss from that entry to that exit.

Every buy & sell, by day

Buy/sell price is the close on that trade’s own date. A closed position (bought, then later sold) shows its realized return. A BUY with no sell yet is still open — its return is unrealized, marked † and marked-to-market against the latest available close.

The stock and buy price for the 5 most recent rows are for Premium members; the next 3 need a free account.

DateActionStockBuy priceSell / current priceReturnWhy
20 Nov 2026BUY🔒 Premium🔒$84.83 (now)+0% †Entered the top 10 by trailing 12-month momentum
20 Nov 2026BUY🔒 Premium🔒$70.75 (now)+0% †Entered the top 10 by trailing 12-month momentum
20 Nov 2026SELL🔒 Premium🔒$105.78-14.2%Dropped out of the top 10, or lost its own 200-day average
20 Nov 2026SELL🔒 Premium🔒$38.85-13.6%Dropped out of the top 10, or lost its own 200-day average
17 Nov 2026BUY🔒 Premium🔒$137.42 (now)-10.9% †Entered the top 10 by trailing 12-month momentum
17 Nov 2026BUY$66.61 (now)-7.5% †Entered the top 10 by trailing 12-month momentum
17 Nov 2026SELL$78.86-5.5%Dropped out of the top 10, or lost its own 200-day average
17 Nov 2026SELL$84.93-14.4%Dropped out of the top 10, or lost its own 200-day average
10 Nov 2026BUYETON$67.54$60.85 (now)-9.9% †Entered the top 10 by trailing 12-month momentum
10 Nov 2026BUYEVC$9.11$8.64 (now)-5.2% †Entered the top 10 by trailing 12-month momentum

1,071 buy/sell rows on file (279 trading-day changes), most recent first — every one of them, not a sample. Of 508 closed round trips with a known price on both ends, 50.4% were profitable and the average trade returned +6.5%.

Scroll to Top